DEA June 29 Hearing Could Decide the Future of Adult-Use Cannabis

The Biggest Cannabis Hearing in a Generation

Mark your calendars: June 29, 2026. That's the date the Drug Enforcement Administration (DEA) will convene what could be the most consequential hearing in the history of American cannabis policy. Set to take place at the DEA Hearing Facility at 700 Army Navy Drive in Arlington, Virginia, and running through July 15, the proceeding will determine whether marijuana rescheduling extends beyond medical products to encompass the entire adult-use market.

The stakes could not be higher. While the Trump administration's April 23 order moved FDA-approved marijuana products and state-licensed medical cannabis into Schedule III of the Controlled Substances Act, recreational marijuana remains firmly planted in Schedule I — the most restrictive federal classification, shared with heroin and LSD. The June hearing is designed to consider whether that distinction should change.

What Already Happened: The Medical Marijuana Milestone

To understand why the June hearing matters so much, it helps to review the groundwork. On April 22, 2026, the Department of Justice issued its final order placing two categories of cannabis products into Schedule III: those with FDA approval and those operating under qualifying state-issued medical marijuana licenses. The move was historic — the first time in over five decades that any form of marijuana had been officially downgraded under federal scheduling.

The reclassification immediately opened doors for medical operators. Tax deductions previously blocked by Section 280E of the Internal Revenue Code became available overnight. Companies like Trulieve rushed to file DEA registration applications, seeking to formalize their operations under the new federal framework. Institutional investors who had long avoided cannabis due to its Schedule I status began circling the industry with renewed interest.

But for the roughly $30 billion adult-use market operating across 24 states, the April order changed nothing. Recreational dispensaries, cultivators, and manufacturers remained federally classified as Schedule I drug traffickers — even in states where voters had explicitly approved legal sales.

What the June Hearing Will Address

The DEA hearing is a formal administrative proceeding, not a congressional vote or executive action. It follows a rulemaking process initiated by the Department of Health and Human Services, which recommended in August 2023 that marijuana be rescheduled from Schedule I to Schedule III based on scientific and medical evidence.

The hearing will consider whether broader rescheduling should apply to all marijuana — not just medical products. Administrative Law Judges will hear testimony from industry stakeholders, medical researchers, law enforcement agencies, and public interest groups. The proceeding must conclude by July 15, though a final ruling could take additional months.

Legal experts widely view the administration's decision to reschedule medical marijuana first as a deliberate strategy. By establishing a defensible legal record for limited rescheduling, the DOJ has built a foundation that could support broader action following the hearing. The phased approach also gave the DEA time to develop registration frameworks and compliance protocols before potentially opening the floodgates to recreational operators.

The 280E Tax Question Looms Large

For adult-use operators, the financial implications of Schedule III status are enormous. Under current law, Section 280E of the Internal Revenue Code prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. For cannabis companies, this has meant effective federal tax rates that sometimes exceed 70 percent — in extreme cases pushing past 90 percent.

Medical operators who now qualify for Schedule III treatment can deduct everything from employee salaries to rent to marketing expenses. Adult-use businesses watching from the sidelines are paying close attention. Industry analysts estimate that extending 280E relief to the entire cannabis sector could save operators hundreds of millions of dollars annually, fundamentally altering profitability calculations and company valuations.

The retroactivity question adds another layer of complexity. Every medical-side cannabis operator filing under 280E from 2014 onward could theoretically file amended returns for open tax years and claim refunds. If adult-use operators eventually receive the same treatment, the IRS could face a wave of refund claims stretching back years.

Public Sentiment Supports Reform

The public is overwhelmingly on the side of further reform. Researchers who analyzed more than 42,000 public comments submitted to the DEA during the rescheduling process found that only 6.7 percent of commenters opposed reform of any kind. Among those favoring change, nearly 30 percent supported the current plan to move cannabis from Schedule I to Schedule III, while a striking 63.5 percent advocated for even greater reform, including complete descheduling.

Those numbers reflect broader polling trends. Gallup's most recent survey found that 70 percent of Americans support full marijuana legalization, a figure that has remained stable for several years. The political calculus has shifted dramatically since the days when cannabis reform was considered a fringe issue.

The Opposition Hasn't Gone Quiet

Despite overwhelming public support, the path forward is far from guaranteed. A lawsuit filed in early May seeks to reverse the medical marijuana rescheduling entirely, arguing that the DOJ exceeded its authority. Conservative advocacy groups and some law enforcement organizations have pushed back against any loosening of federal restrictions.

There's also the question of congressional action. Some legislators have signaled they could use the Congressional Review Act to block the rescheduling order, though such a move would require bipartisan support that appears unlikely given the political dynamics.

The marijuana industry itself is not entirely unified. Some medical operators worry that extending Schedule III to adult-use products could increase competition and dilute the regulatory advantages they've secured. State regulators face questions about how federal changes would interact with existing licensing frameworks.

What Operators Should Do Now

Industry attorneys are advising cannabis businesses to prepare for multiple outcomes. For medical operators, the immediate priority is completing DEA registration before the 60-day expedited window closes. For adult-use companies, the guidance is more nuanced: prepare financial models for both scenarios, document expenses meticulously in case 280E relief becomes retroactive, and engage with industry associations pushing for inclusive rescheduling.

The hearing also presents an opportunity for public participation. Stakeholders who wish to testify or submit written comments should monitor the Federal Register for updated procedural guidance. The DEA has indicated it will accommodate a broad range of perspectives, though the formal hearing process requires advance registration.

What Comes After the Hearing

Even if the hearing produces a favorable recommendation, the timeline for final action remains uncertain. Administrative Law Judges will issue findings that the DEA administrator must then consider before publishing a final rule. That process could stretch into late 2026 or early 2027.

Meanwhile, the cannabis industry continues to operate in a split reality. Medical operators in states with qualifying licenses are integrating into the federal regulatory framework for the first time. Adult-use businesses are watching, waiting, and hoping that June 29 marks the beginning of the end for one of the most consequential regulatory disparities in American drug policy.

One thing is clear: the June 29 hearing represents the industry's best shot at comprehensive federal reform through the administrative process. Whatever happens in that Arlington hearing room will shape the trajectory of American cannabis policy for years to come.

For readers ready to take the next step, Budpedia maintains the most comprehensive cannabis dispensary directory in the United States — license-verified, with hours, menus, and real reviews for every listing across 48 legal states.